1. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial
- Author
-
Hurrell, Alice, Webster, Louise, Sparkes, Jenie, Battersby, Cheryl, Brockbank, Anna, Clark, Katherine, Duhig, Kate E, Gill, Carolyn, Green, Marcus, Hunter, Rachael M, Seed, Paul T, Vowles, Zoe, Myers, Jenny, Shennan, Andrew H, Chappell, Lucy C, Ahuja, Ashwin, Alexander, Hazel, Arya, Rita, Bahl, Rachna, Bapir, Mihraban, Barry, Natalie, Basak, Sambita, Bishop, Linda, Biswas, Chandrima, Campbell, Deniesha, Chados, Nikolaos, Davies, Sarah, Davison, Jessica, Dudgeon, Lucy, Ferry, Orla, Ficquet, Jo, Girling, Jo, Gowans, Sharon, Hewitt, Lesley, Hinshaw, Kim, Holt, Siobhan, Jack, Elaine, Jennings, Jacqui, Maher, Martin, McBean, Mel, McDonnell, Sian, Mehta, Anku, Morris, Katie, O'Brien, Clare, Obiozo, Chinwe, Peers, Beth, Pickering, Francis, Regan, Maeve, Rich, Mel, Roughley, Lindsay, Ryan, Grace, Sharp, Andrew, Smart, Brittany, Smith, Annabel, Stirrat, Laura, Thompson, Hilary, Trepte, Lauren, Verghese, Lynda, Willson, Seren, and Yulia, Angela
- Abstract
Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia.
- Published
- 2024
- Full Text
- View/download PDF